Novo Nordisk AS (HAM:NOV) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:NOV Novo Nordisk AS HAM:NOV
82 GF Score
Price €43.42
GF Value €120.28
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS FFO per Share?

FFO per Share only applies to REITs.

HAM:NOV
82GF Score
Novo Nordisk AS HAM:NOV
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (HAM:NOV) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.42 is trading 63.9% below its estimated GF Value™ of €120.28. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for HAM:NOV:

  • FFO per Share:
  • GF Value™: €120.28 vs. price of €43.42 (63.9% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the HAM:NOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
82GF Score

Get the complete analysis for HAM:NOV

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.42
Price
€120.28
GF Value